Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes

• Verfasst von: Steg, P. Gabriel [VerfasserIn]
• Verfasst von: Harrington, Robert A. [VerfasserIn]
• Verfasst von: Emanuelsson, Håkan [VerfasserIn]
• Verfasst von: Katus, Hugo [VerfasserIn]
• Verfasst von: Mahaffey, Kenneth W. [VerfasserIn]
• Verfasst von: Meier, Bernhard [VerfasserIn]
• Verfasst von: Storey, Robert F. [VerfasserIn]
• Verfasst von: Wojdyla, Daniel M. [VerfasserIn]
• Verfasst von: Lewis, Basil S. [VerfasserIn]
• Verfasst von: Maurer, Gerald [VerfasserIn]
• Verfasst von: Wallentin, Lars [VerfasserIn]
• Verfasst von: James, Stefan K. [VerfasserIn]
• Titel: Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes
• Verf.angabe: P. Gabriel Steg, Robert A. Harrington, Håkan Emanuelsson, Hugo A. Katus, Kenneth W. Mahaffey, Bernhard Meier, Robert F. Storey, Daniel M. Wojdyla, Basil S. Lewis, Gerald Maurer, Lars Wallentin, Stefan K. James for the PLATO Study Group
• Jahr: 2013
• Umfang: 11 S.
• Fussnoten: Gesehen am 15.02.2022
• Titel Quelle: Enthalten in: Circulation
• Ort Quelle: Philadelphia, Pa. : Lippincott, Williams & Wilkins, 1950
• Jahr Quelle: 2013
• Band/Heft Quelle: 128(2013), 10, Seite 1055-1065
• ISSN Quelle: 1524-4539
• DOI: doi:10.1161/CIRCULATIONAHA.113.002589
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: blood platelets
• Sach-SW: stents
• Sach-SW: thrombosis
• K10plus-PPN: 1789622859

Abstract

Background— - - We aimed to describe the effects of ticagrelor versus clopidogrel on stent thrombosis in the Platelet Inhibition and Patient Outcomes (PLATO) trial. - - Methods and Results— - - Of 18 624 patients hospitalized for acute coronary syndromes, 11 289 (61%) had at least 1 intracoronary stent. Ticagrelor reduced stent thrombosis compared with clopidogrel across all definitions: definite, 1.37% (n=71) versus 1.93% (n=105; hazard ratio [HR], 0.67; 95% confidence interval [CI], 0.50-0.90; P=0.0091); definite or probable, 2.21% (n=118) versus 2.87% (n=157; HR, 0.75; 95% CI, 0.59-0.95; P=0.017); and definite, probable, and possible, 2.94% (n=154) versus 3.77 (n=201; HR, 0.77; 95% CI, 0.62-0.95). The reduction in definite stent thrombosis was consistent regardless of acute coronary syndrome type, presence of diabetes mellitus, stent type (drug-eluting or bare metal stent), CYP2C19 genetic status, loading dose of aspirin, dose of clopidogrel before randomization, and use of glycoprotein IIb/IIIa inhibitors at randomization. The reduction in stent thrombosis with ticagrelor was numerically greater for late (>30 days; HR, 0.48; 95% CI, 0.24-0.96) and subacute (4 hours-30 days; HR, 0.60; 95% CI, 0.39-0.93) compared with acute (<24 hours; HR, 0.94; 95% CI, 0.43-2.05) stent thrombosis or for patients compliant to therapy (ie, taking blinded study treatment ≥80% of the time) compared with less compliant patients. Randomization to ticagrelor was a strong independent inverse predictor of definite stent thrombosis (HR, 0.65; 95% CI, 0.48-0.88). - - Conclusion— - - Ticagrelor compared with clopidogrel reduces the incidence of stent thrombosis in patients with acute coronary syndromes, with consistent benefit across a broad range of patient, stent, and treatment characteristics. - - Clinical Trial Registration— - - URL: http://www.clinicaltrials.gov. Unique identifier: NCT00391872.